 This is a multicenter non-comparative phase III protocol, which predicts the inclusion of 30 patients with 25 patients infected with CMV, to demonstrate efficiency of 55 with a minimum required efficiency of 30, an alpha risk of 10 and a strength of 90. The main purpose of the study is to evaluate the efficiency of this treatment on the level of CMV viral replication 21 days after the first injection. A positive response is defined by a viral load became undetectable or reduced by at least 2 log10. A negative response is defined on the basis of unchanged or increased viral load after injection of T cells; a partial response is defined as a significant decrease greater than 0.3log10 copies ml but less than 2 log10 of the viral load, which still remains above the detection threshold. For patients with an isolated organ damage patient without PCR, a positive response is defined by the healing of the affected organ. In case of negative or partial response 21 days after the first injection, a second injection if available can be programmed in the absence of clinical signs of graft versus host or aggravation of pre-existing GVHa. The secondary purposes are: a assess the tolerance, in terms of occurrence of acute reaction graft versus host GVHa directly due to the injection of T cells ; b evaluation of indirect biological parameters of efficiency such as injected T cells expansion studied using tetramers specific secretion of IFN-g; c the study of efficiency and tolerance of this immunotherapy against adenovirus. Inclusion criteria concern children and adults who have received allogenic transplant of HSC, which donor is CMV and having an active viral infection: 1 in conventional antiviral treatment failure, with a persistent viral load andor increased after 15 days of treatment or with CMV or ADV disease with organ damage documented without systemic replication if possible, with a CMV PCR or ADV PCR positive in the organ, or 2 in intolerance or toxicity situation of this treatment which prevents its pursuit. Donor T cells will be injected if the following conditions are observed : 1 donor chimerism 10, 2 absence of GvHa grade II 3 absence of severe organ failure. The antiviral drug therapy may eventually be continued jointly with cellular immunotherapy. 